Project Grant R01HL182024
Award Date 8/17/26
Completion Date 5/31/30
Dollars Obligated $800K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $643,349 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 17, 2026, to investigate the role of gasdermin D (GSDMD) inhibition in reducing inflammation-related atrial fibrillation risk associated with clonal hematopoiesis and aging. The research employs bone marrow transplantation, deep cardiac phenotyping, single-cell transcriptomics, and genetic analyses to elucidate how clonal...
- The National Heart Lung and Blood Institute awarded Brigham & Women's Hospital $1.702 million on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a small activating RNA (saRNA) therapeutic approach for treating atherosclerotic cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis (MASH). The project restores macrophage efferocytosis—the clearance of dead cells—by reactivating the TIM4 receptor on macrophages using...
- Federal Grant Award Summary Baylor College of Medicine received a $673,598 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with a completion date of June 30, 2029. The project, "Cardiomyocyte-Fibroblast Signaling in Atrial Fibrillation," delivers basic and translational research services investigating molecular mechanisms underlying atrial fibrillation (AF), a...
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $608,173 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the stretch-activated PIEZO1 channel in heart failure-associated atrial fibrillation. The research comprises three aims: testing the hypothesis that atrial stretch-induced PIEZO1 activation contributes to pathological atrial remodeling and atrial fibrillation predisposition...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $701,116 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate transcriptional mutagenesis as a novel mechanism driving heart failure. The research examines how oxidative stress promotes formation of 8-oxo-deoxyguanosine lesions in DNA, which disrupts transcriptional fidelity in cardiomyocytes. Aim 1 integrates long-read single-nucleus RNA sequencing from human heart...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $158,892 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the impact of DNMT3A protein reduction on normal and clonal hematopoiesis. The research investigates mechanisms by which somatic DNMT3A mutations drive clonal hematopoiesis—the clonal expansion of mutated hematopoietic stem and progenitor cells—which accelerates with age and increases the risk of hematologic...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,500 on March 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage biology in atherosclerosis and atherosclerosis-related cardiometabolic disease. The award funds a comprehensive program exploring the role of macrophage efferocytosis and resolution cycles in promoting fibrous cap thickening in atherosclerotic plaques and...
- The National Heart Lung and Blood Institute awarded President and Fellows of Harvard College $151,040 on February 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of TOLLOID proteases in atrial fibrosis and atrial fibrillation pathogenesis. The research uses gene-edited mouse models, both with and without surgically induced atrial fibrosis, to examine how TOLLOID protease-mediated cleavage of Growth Differentiation Factor 11 (GDF11) regulates...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $670,574 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, to conduct research on diurnal adipose-heart lipid dynamics in the obesity paradox of heart failure. The research investigates why patients with higher body mass index experiencing heart failure exhibit better prognosis than those with lower BMI, despite obesity being a heart failure risk factor. The project tests the...
- The National Heart, Lung, and Blood Institute awarded the University of South Florida $2.186 million on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the relationship between atrial microvascular and endothelial dysfunction and postoperative atrial fibrillation. The research evaluates microvascular signaling pathways responsible for myogenic, vasomotor, and endothelial dysfunction of the atrial microvasculature in patients with...